RxDoctor Payments Data

Kristopher Fannin, MD

Family Medicine · Louisville, KYNPI 1477795920

Payments from drug & device makers

$5,763in general payments, 2019–2025

Across 230 payments — averaging $25.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • AbbVie$728
  • Pfizer$612
  • Amgen$253
  • Johnson & Johnson$232
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$5,746100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,763 in reported general payments places this provider in the 85th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$93,215
Medicare patients
212
Services billed
1,408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide129$143,184
EliquisApixaban132$133,337
Breztri AerosphereBudesonide/Glycopyr/Formoterol70$58,396
XareltoRivaroxaban39$50,688
JardianceEmpagliflozin37$49,286
Tresiba Flextouch U-200Insulin Degludec47$46,324
FarxigaDapagliflozin Propanediol30$41,351
MyrbetriqMirabegron35$37,526
MounjaroTirzepatide18$19,676
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$16,954
SymbicortBudesonide/Formoterol Fumarate39$16,380
LinzessLinaclotide15$16,044
Bydureon BciseExenatide Microspheres13$15,958
VascepaIcosapent Ethyl13$13,344
BrilintaTicagrelor11$8,735

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,267$143,184129 claims
PfizerEliquis$612$133,337132 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort, Brilinta$1,528$124,862150 claims
Johnson & JohnsonXarelto$232$50,68839 claims
Boehringer IngelheimJardiance$48$49,28637 claims
AbbVieLinzess, Synthroid$728$18,50648 claims
GSKTrelegy Ellipta$15$16,95416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →